Read by QxMD icon Read

Oxaliplatin gemox

Dominique Béchade, Marie Desjardin, Emma Salmon, Grégoire Désolneux, Yves Bécouarn, Serge Evrard, Marianne Fonck
Pancreatic acinar cell carcinoma (ACC) is a rare malignant neoplasm that accounts for 1-2% of all pancreatic neoplasms. Here we report two cases of ACC and describe their clinical features, the therapies used to treat them, and their prognosis. The first patient was a 65-year-old woman who had an abdominal CT scan for a urinary infection. Fortuitously, a rounded and well-delimited corporeal pancreatic tumor was discovered. An endoscopic ultrasound (EUS)-guided fine needle aspiration revealed an ACC. During the puncture, a hypoechoic cavity appeared inside the lesion, corresponding to a probable necrotic area...
January 2016: Case Reports in Gastroenterology
Sihem Sebbagh, Julia Roux, Chantal Dreyer, Cindy Neuzillet, Armand de Gramont, Cecilia Orbegoso, Olivia Hentic, Pascal Hammel, Aimery de Gramont, Eric Raymond, Thierry André, Benoist Chibaudel, Sandrine Faivre
BACKGROUND: Gemcitabine (GEM)-platinum chemotherapy stands as first-line therapy for patients with recurrent/advanced biliary tract cancer (BTC), yielding progression-free survival (PFS) of 3.4-6.4 months. No standard second-line chemotherapy after GEM-platinum failure exists and data on survival benefit remain limited. MATERIAL AND METHODS: We retrospectively reviewed patients with recurrent/advanced BTC who received gemcitabine-oxaliplatin (GEMOX)-based chemotherapy followed by 5-fluorouracil-irinotecan (FOLFIRI)-based chemotherapy to evaluate the efficacy of the sequential treatment strategy...
June 22, 2016: Acta Oncologica
Xiao-Mei Jing, Zhi-Hui Zhang, Ping Wu, Shi-Chuan Zhang, Yuan-Rong Ren, Zhu-Juan Xiong, Wen Wei, Lei Luo, Li Li
Extranodal nature killer (NK)/T cell lymphoma (ENKL), nasal type, is a highly aggressive and heterogeneous disease. Here we report a retrospective study of 38 newly-diagnosed ENKL patients treated with pegaspargase, gemcitabine, oxaliplatin (P-Gemox) and sandwiched radiotherapy in our department during 2012-2016. A median of 4 (range, 2-6) (total=141) cycles of P-Gemox were administered. Interim restaging after at least 2 cycles showed complete remission (CR) rate of 23.68%, partial remission (PR) rate of 63...
August 2016: Leukemia Research
Mohamed Elshebeiny, Walid Almorsy
BACKGROUND: Patients with platinum-resistant epithelial ovarian cancer (EOC) experience poor outcome. Currently, no clearly superior management strategy exists for platinum-resistant EOC patients. PURPOSE: Analyze the efficacy and safety of gemcitabine-oxaliplatin (GEMOX) in platinum resistant EOC patients. PATIENTS AND METHODS: Thirty-two patients with platinum-based resistant EOC were included. Studied patients had received GEM at the dose of 1000mg/m(2) on days 1 and 8 and OX 100mg/m(2) on day 1, administered over 2h 30min after GEM infusion of 3week treatment cycle...
September 2016: Journal of the Egyptian National Cancer Institute
Antònia Obrador-Hevia, Margalida Serra-Sitjar, José Rodríguez, Lamiae Belayachi, Leyre Bento, Marta García-Recio, Jose María Sánchez, Priam Villalonga, Antonio Gutiérrez, Silvia Fernández de Mattos
Mantle Cell Lymphoma (MCL) is an aggressive lymphoma subtype that accounts for 6-8% of non-Hodgkin lymphomas. The disease is mostly incurable and characterized by a continuous pattern of relapse. Major changes have recently been implemented in the management of MCL, but continuous relapses still mark this disease as a challenge for clinicians. We previously reported the efficacy of GemOx-R (Gemcitabine, Oxaliplatin and Rituximab) in patients with refractory and relapsing MCL. We present results for a larger series with longer follow-up and including high-risk frontline patients, showing an overall response rate of 83%...
September 2016: British Journal of Haematology
Nai-Jung Chiang, Chiun Hsu, Jen-Shi Chen, Hsiao-Hui Tsou, Ying-Ying Shen, Yee Chao, Ming-Huang Chen, Ta-Sen Yeh, Yan-Shen Shan, Shiu-Feng Huang, Li-Tzong Chen
Aberrant expression of ROS1, ALK or c-MET (RAM) is implicated in carcinogenesis and cancer drug resistance. We retrospectively evaluated the effect of RAM expression on outcomes for advanced biliary tract cancer patients, who were treated with gemcitabine plus oxaliplatin (GEMOX), with or without cetuximab, in a randomized phase II trial. RAM expression levels on archived tissue sections were scored using immunohistochemistry (IHC). Of 110 tumors with IHC staining for all three markers, 18 were RAM(high) (IHC intensity 3+ for any markers)...
2016: Scientific Reports
T Walter, D Planchard, K Bouledrak, J Y Scoazec, P J Souquet, A S Dussol, J Guigay, V Hervieu, A Berdelou, M Ducreux, D Arpin, C Lombard-Bohas, E Baudin
OBJECTIVES: The aim of this retrospective study was to analyse the efficacy of gemcitabine-oxaliplatin (gemox) or 5-fluorouracil-oxaliplatin (folfox) in the treatment of metastatic pulmonary carcinoid tumors. PATIENTS AND METHODS: 45 patients were included in two tertiary referral centers between January 1999 and January 2013. Typical, atypical carcinoids or not otherwise specified carcinoids were diagnosed according to WHO criteria in 19%, 57%, and 24% of cases by two expert pathologists...
June 2016: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
Jing-Hua Wang, Liang Wang, Cheng-Cheng Liu, Zhong-Jun Xia, Hui-Qiang Huang, Tong-Yu Lin, Wen-Qi Jiang, Yue Lu
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Asparaginase-based regimens are recommended for patients with advanced-stage or relapsed/refractory ENKTL. We retrospectively investigated the efficacy and toxicity of combined gemcitabine, oxaliplatin, and pegaspargase (P-gemox) in these patients. A total of 35 patients with newly diagnosed stage III-IV, relapsed or refractory ENKTL were treated with 2 to 8 cycles of P-gemox: gemcitabine (1250 mg/m2) and oxaliplatin (85 mg/m2) injected intravenously and pegaspargase (2500 IU/m2) injected intramuscularly on day 1 and repeated every 2 weeks...
May 17, 2016: Oncotarget
Jing-Hua Wang, Hua Wang, Yan-Jun Wang, Zhong-Jun Xia, Hui-Qiang Huang, Wen-Qi Jiang, Yue Lu
Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive neoplasm with a poor outcome. Novel L-asparaginase-based treatment regimens, such as GELOX (gemcitabine, oxaliplatin, and L-asparaginase) and P-gemox (gemcitabine, oxaliplatin, and pegaspargase), have shown promising results against stage IE/IIE ENKTL. To define the general applicability of P-gemox, in a retrospective analysis we examined the efficacy and safety of P-gemox in a cohort of 117 patients with newly diagnosed or relapsed/refractory ENKTL...
June 7, 2016: Oncotarget
Francesca Spada, Lorenzo Antonuzzo, Riccardo Marconcini, Davide Radice, Andrea Antonuzzo, Sergio Ricci, Francesco Di Costanzo, Annalisa Fontana, Fabio Gelsomino, Gabriele Luppi, Elisabetta Nobili, Salvatore Galdy, Chiara Alessandra Cella, Angelica Sonzogni, Eleonora Pisa, Massimo Barberis, Nicola Fazio
PURPOSE: The role of chemotherapy in low-/intermediate-grade neuroendocrine tumors (NETs) is still debated. We present the results of an Italian multicenter retrospective study evaluating activity and toxicity of oxaliplatin-based chemotherapy in patients with advanced NETs. METHODS: Clinical records from 5 referral centers were reviewed. Disease control rate (DCR) corresponding to PR + SD (partial response + stable disease) at 6 months, progression-free survival (PFS), overall survival (OS) and toxicity were calculated...
2016: Neuroendocrinology
Anne Ploquin, Capucine Baldini, Perrine Vuagnat, Samira Makhloufi, Christophe Desauw, Mohamed Hebbar
Pancreatic acinar cell carcinoma (ACC) is a rare entity. Herein we present the case of a 50-year-old male patient with an unlimited mass on the pancreatic corpus and tail with peripancreatic effusion and multiple metastases in the liver and spleen. A liver biopsy showed a pancreatic ACC. The patient received 9 cycles of gemcitabine plus oxaliplatin (GEMOX regimen), which had to be stopped because of a persistent grade 2 neuropathy. A CT scan showed complete response after 14 years. At the age of 61 years, a localized prostatic cancer was diagnosed, treated by prostatectomy...
September 2015: Case Reports in Oncology
Shrey Modi, Devika Kir, Bhuwan Giri, Kaustav Majumder, Nivedita Arora, Vikas Dudeja, Sulagna Banerjee, Ashok K Saluja
INTRODUCTION: Oxaliplatin is part of pancreatic cancer therapy in the FOLFIRINOX or GEMOX/XELOX regimen. DNA damage repair is one of the factors responsible for oxaliplatin resistance that eventually develops in this cancer. Triptolide/Minnelide has been shown to be effective against pancreatic cancer in preclinical trials. In this study, we evaluated the efficacy of combination of triptolide and oxaliplatin against pancreatic cancer. METHODS: Highly aggressive pancreatic cancer cells (MIA PaCa-2 and PANC-1) were treated with oxaliplatin (0-10 μM), low-dose triptolide (50 nM), or a combination of both for 24-48 h...
January 2016: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
Yingqiang Jiang, Hui Zhong, Ping He, Lianxi Zheng, Ke Yang
OBJECTIVE: To evaluate the safety and efficacy of gemcitabine combined with S-1 in the treatment of advanced pancreatic cancer. METHODS: A retrospective analysis of the clinical data of 49 patients with advanced pancreatic cancer, who did not receive radiotherapy and chemotherapy, were divided into two groups: the study group (25 cases), and control group (24 cases). Patients in the study group received gemcitabine 1 000 mg/m² via intravenous drip at the first and 8th days, and received S-1 80 mg/m², morning and evening (twice a day) for the first 14 days, and 21 days as a treatment cycle of chemotherapy...
June 2015: Zhonghua Zhong Liu za Zhi [Chinese Journal of Oncology]
Seung Tae Kim, Kee-Taek Jang, Su Jin Lee, Hye-Lim Jang, Jeeyun Lee, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park
BACKGROUND: The aim of this study was to determine whether early tumor shrinkage (ETS) at 6 weeks after treatment correlates with progression-free survival (PFS) and overall survival (OS) in advanced biliary tract cancer (BTC) patients receiving gemcitabine plus oxaliplatin (GEMOX), with or without erlotinib. METHODS: This was a multicenter, open label, randomized, phase III trial of 103 BTC patients ( Identifier; NCT01149122, and Rigistration date; January, 7, 2010), comparing GEMOX with GEMOX plus erlotinib...
2015: BMC Cancer
Anne-Sophie Dussol, Marie-Odile Joly, Cecile Vercherat, Julien Forestier, Valérie Hervieu, Jean-Yves Scoazec, Catherine Lombard-Bohas, Thomas Walter
BACKGROUND: The alkylating agents (ALKYs) streptozotocin, dacarbazine, and temozolomide currently are the main drugs used in systemic chemotherapy for neuroendocrine tumors (NETs). The promising activity shown by gemcitabine and oxaliplatin (GEMOX) in previous studies prompted this study 1) to confirm the use of GEMOX in a larger population of NET patients, 2) to compare its efficacy with that of ALKYs, and 3) to explore whether the O(6) -methylguanine-DNA methyltransferase (MGMT) status could help in selecting the chemotherapy regimen...
October 1, 2015: Cancer
Bi-Ling Chen, Zhe Zhao, Shi-Hai Qin, Li Liu, Qing-Ling Tan
OBJECTIVE: To investigate the short-term efficacy and safety of GEMOX regimen for the treatment of lymphoma, so as to provide the reference for further rational selection of chemotherapy. METHODS: A total of 61 patients with relapse and refractory non-Hodgkin's lymphoma (NHL) treated with chanotherapy of GEMOX regimen from 2010 Jannary -2013 year were selected, and their clinical data were collected, and the short-term efficacy, toxic effects and short-term survival were analyzed...
April 2015: Zhongguo Shi Yan Xue Ye Xue za Zhi
Dushyant V Sahani, Koichi Hayano, Anna Galluzzo, Andrew X Zhu
OBJECTIVE: The purpose of this study was to evaluate the response of biliary tract cancer treated with multidrug chemotherapy using FDG PET in comparison with morphologic and density changes. MATERIALS AND METHODS: In this phase II clinical trial, 28 patients with unresectable or metastatic biliary tract cancers treated with gemcitabine and oxaliplatin combined with bevacizumab (GEMOX-B) underwent FDG PET and contrast-enhanced CT at baseline and after the second cycle of the therapy (8 weeks)...
April 2015: AJR. American Journal of Roentgenology
Seung Tae Kim, Kee-Taek Jang, Jeeyun Lee, Heung-Moon Jang, Hye-Jin Choi, Hye-Lim Jang, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Joon Oh Park
BACKGROUND: We previously reported that the addition of erlotinib to gemcitabine and oxaliplatin (GEMOX) resulted in greater antitumor activity and might be a treatment option for patients with biliary tract cancers (BTCs). Molecular subgroup analysis of treatment outcomes in patients who had specimens available for analysis was undertaken. METHODS: Epidermal growth factor receptor (EGFR), KRAS, and PIK3CA mutations were evaluated using peptide nucleic acid-locked nucleic acid polymerase chain reaction clamp reactions...
February 2015: Translational Oncology
Ying Liu, Han Yue, Shuning Xu, Feng Wang, Ning Ma, Ke Li, Lei Qiao, Jufeng Wang
BACKGROUND: Because of the poor prognosis of unresectable or metastatic hepatocellular carcinoma there is a need for effective systemic therapy. The purpose of this study was to assess the efficacy and safety of gemcitabine and oxaliplatin (GEMOX) combined with sorafenib, as first-line therapy, followed by sorafenib as maintenance therapy for patients with advanced hepatocellular carcinoma (HCC). METHODS: In this open-label, multicenter, single-group, prospective study, eligible patients with advanced HCC received oral sorafenib 400 mg twice daily, gemcitabine 1,000 mg/m(2) intravenously (i...
October 2015: International Journal of Clinical Oncology
J S Chen, C Hsu, N J Chiang, C S Tsai, H H Tsou, S F Huang, L Y Bai, I C Chang, H S Shiah, C L Ho, C J Yen, K D Lee, C F Chiu, K M Rau, M S Yu, Y Yang, R K Hsieh, J Y Chang, Y S Shan, Y Chao, L T Chen
BACKGROUND: Previous clinical trials have not proved that adding epidermal growth factor receptor inhibitors to chemotherapy confers a survival benefit for patients with advanced biliary tract cancer (ABTC). Whether the KRAS mutation status of tumor cells confounded the results of past studies is unknown. PATIENTS AND METHODS: ABTC patients stratified by KRAS status, Eastern Cooperative Oncology Group performance status, and primary tumor location were randomized 1 : 1 to receive GEMOX (800 mg/m(2) gemcitabine and 85 mg/m(2) oxaliplatin) or C-GEMOX (500 mg/m(2) cetuximab plus GEMOX) every 2 weeks...
May 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"